Sab Biotherapeutics Inc (SABS) Stock Price, Quote & News

Company Profile

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Flo...

Industry: Biotechnology

Sector: Healthcare

Phone: 305 845 2813

Website: www.sab.bio

Address:

777 W 41st St., Miami Beach, United States

LewisDaKat Jul. 30 at 7:00 PM

$SABS SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET https://marketwirenews.com/stock/sabs/news/sab-bio-to-host-second-quarter-2026-financial-result-4749300068815004.html?utm_source=stocktwits

0 · Reply

DDiamond_Handz Jul. 30 at 5:41 PM

$SABS 10$ eoy

0 · Reply

JTebow_CWS Jul. 30 at 11:47 AM

$SABS Institutional ownership is up to 90%. Loaded the boat.

0 · Reply

Orlandotrader Jul. 27 at 5:34 PM

$SABS This one is just marking time. Results 2027. No one will commit early in Bio Tech. Patience and load in lower 3$ Range.

0 · Reply

high_tech_texan Jul. 25 at 11:51 AM

$SABS These two positions are still open (from a couple of week ago): * Vice President Quality Assurance * Senior Research Associate 2, Bioanalytical Assays These TEN new job openings have just been added: * Clinical Sample Manager * Clinical Trial Manager, Immunology * Executive Director, Pharmacovigilance (PV) * Quality Systems Specialist * Research Associate 1, Antigen Production * Senior Quality Assurance Specialist * Senior Training Manager, Quality Assurance * Sr. Director, Medical Writing – Biologics * Vice President Manufacturing * Vice President Regulatory Affairs

2 · Reply

BioRich Jul. 21 at 4:42 PM

$FDMT continues to get attention. New to many so take a look and let me know your thoughts. $IBRX, $SMMT $SABS and $VKTX also leading the first half of the day. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more( money. Cheers!

0 · Reply

stockboyaisle1 Jul. 21 at 1:24 PM

$SABS This guy does an amazing job of explaining 142: https://x.com/anthonystaj/status/2033274287415517322/video/1?s=46

0 · Reply

gobio Jul. 20 at 3:47 PM

$SABS https://www.biospace.com/drug-development/type-1-diabetes-pipeline-making-remarkable-progress-toward-insulin-independence?utm_campaign=Newsletter%20%7C%20GenePool&utm_medium=email&_hsenc=p2ANqtz-_nghluMigmY8U5jxGxzp0jn2DdVQ_oDx1-jDxUV-ZGjMkkjwTqFy8ObrILtJCGpqtxYuL9IITVpmCFmJ2k0O9Rns9EEQ&_hsmi=429206667&utm_content=429206667&utm_source=hs_email

0 · Reply

GlobalMarketBulletin Jul. 18 at 9:06 AM

$SABS SAB Biotherapeutics Inc. (SABS) has a $13 analyst target and a promising type 1 diabetes therapy. Could this biotech stock under $5 deliver massive upside? https://globalmarketbulletin.com/is-sab-biotherapeutics-sabs-an-undervalued-biotech-stock-ready-to-take-off/

0 · Reply

GlobalMarketBulletin Jul. 18 at 8:25 AM

$ATAI $LRMR $SABS $VSTM $SOC Wall Street sees triple-digit upside in several of these stocks under $10. Discover the biotech, healthcare, energy, and cryptocurrency names investors are closely watching. https://globalmarketbulletin.com/10-stocks-under-10-analysts-believe-could-soar-200/

2 · Reply

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

2026-06-24T11:25:10.000Z - 5 weeks ago

SAB Biotherapeutics initiated with an Overweight at Barclays

May 29, 2026, 8:00 AM EDT - 2 months ago

SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

2026-05-22T09:15:45.000Z - 2 months ago

SAB Biotherapeutics initiated with a Buy at Citi

2026-05-20T09:05:51.000Z - 2 months ago

SAB Biotherapeutics initiated with a Buy at Jefferies

May 13, 2026, 7:00 AM EDT - 2 months ago

SAB Biotherapeutics Slides: Corporate presentation

2026-05-12T18:00:35.000Z - 2 months ago

SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright

May 12, 2026, 8:30 AM EDT - 2 months ago

SAB Biotherapeutics Earnings Call Transcript: Q1 2026

May 12, 2026, 8:30 AM EDT - 2 months ago

SAB Biotherapeutics Earnings release: Q1 2026

May 12, 2026, 8:30 AM EDT - 2 months ago

SAB Biotherapeutics Quarterly report: Q1 2026

May 12, 2026, 7:30 AM EDT - 2 months ago

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

May 5, 2026, 8:30 AM EDT - 3 months ago

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

Apr 30, 2026, 8:00 AM EDT - 3 months ago

SAB Biotherapeutics Proxy statement: Proxy filing

2026-04-29T12:30:52.000Z - 3 months ago

Emergent BioSolutions enters SAB-142 development pact with SAB Biotherapeutics

EBS

Apr 22, 2026, 7:00 AM EDT - 3 months ago

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

2026-04-02T11:26:22.000Z - 4 months ago

SAB Biotherapeutics initiated with a Buy at Rodman & Renshaw

Mar 19, 2026, 4:01 PM EDT - 4 months ago

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

2026-03-18T10:12:35.000Z - 4 months ago

SAB Biotherapeutics 19.325M share Spot Secondary priced at $3.85

Mar 17, 2026, 10:46 PM EDT - 4 months ago

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

2026-03-17T21:35:16.000Z - 4 months ago

SAB Biotherapeutics $75M Spot Secondary; price range $3.75-$4.07

2026-03-17T20:05:50.000Z - 4 months ago

SAB Biotherapeutics announces common stock offering, no amount given

Mar 17, 2026, 4:01 PM EDT - 4 months ago

SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

2026-03-10T23:25:30.000Z - 5 months ago

SAB Biotherapeutics price target raised to $14 from $12 at Chardan

2026-03-10T11:41:43.000Z - 5 months ago

SAB Biotherapeutics announces additional Phase 1 data for SAB-142

Mar 10, 2026, 7:31 AM EDT - 5 months ago

SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

Mar 9, 2026, 5:16 PM EDT - 5 months ago

SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

Mar 9, 2026, 3:00 PM EDT - 5 months ago

SAB Biotherapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 7:00 AM EDT - 5 months ago

SAB Biotherapeutics Earnings release: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 5 months ago

SAB Biotherapeutics Annual report: Q4 2025

Mar 2, 2026, 9:00 AM EST - 5 months ago

SAB BIO to Participate in Upcoming Investor Conferences

Feb 25, 2026, 8:40 AM EST - 5 months ago

SAB Biotherapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 11, 2026, 10:30 AM EST - 6 months ago

SAB Biotherapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Jan 15, 2026, 10:30 AM EST - 7 months ago

SAB Biotherapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 7 months ago

SAB Biotherapeutics Slides: Corporate presentation

2026-01-07T13:27:50.000Z - 7 months ago

SAB Biotherapeutics initiated with a Buy at UBS

2026-01-07T13:12:17.000Z - 7 months ago

SAB Biotherapeutics appoints David Zaccardelli as board chair

Jan 7, 2026, 8:00 AM EST - 7 months ago

SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

Jan 6, 2026, 8:00 AM EST - 7 months ago

SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-12-30T15:15:19.000Z - 7 months ago

SAB Biotherapeutics files $300M mixed securities shelf

Dec 29, 2025, 7:00 AM EST - 7 months ago

SAB Biotherapeutics Registration statement: Registration Filing

2025-12-19T11:36:31.000Z - 7 months ago

SAB Biotherapeutics initiated with a Buy at Guggenheim

2025-12-18T13:05:56.000Z - 8 months ago

SAB Biotherapeutics announces first patient dosed in SAFEGUARD trial

Dec 18, 2025, 8:00 AM EST - 8 months ago

First Patient Dosed in SAB BIO's SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D

2025-12-17T13:12:49.000Z - 8 months ago

SAB Biotherapeutics Phase 1 trial of SAB-142 met primary endpoint

Dec 17, 2025, 8:00 AM EST - 8 months ago

SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D

Dec 8, 2025, 8:00 AM EST - 8 months ago

SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management

Dec 2, 2025, 3:50 PM EST - 8 months ago

SAB Biotherapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 14, 2025, 4:00 PM EST - 9 months ago

SAB Biotherapeutics Earnings release: Q3 2025

Nov 14, 2025, 4:00 PM EST - 9 months ago

SAB Biotherapeutics Quarterly report: Q3 2025

Nov 13, 2025, 5:00 PM EST - 9 months ago

SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights

Nov 12, 2025, 10:00 AM EST - 9 months ago

SAB Biotherapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 2:45 PM EST - 9 months ago

SAB Biotherapeutics Transcript: UBS Global Healthcare Conference 2025

Nov 4, 2025, 8:30 AM EST - 9 months ago

SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142

Sep 22, 2025, 8:00 AM EDT - 11 months ago

SAB Biotherapeutics Registration statement: Registration Filing

Sep 19, 2025, 7:24 AM EDT - 11 months ago

SAB BIO Highlights Data in Multiple Presentations at EASD

Sep 3, 2025, 4:05 PM EDT - 11 months ago

SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

Sep 2, 2025, 8:00 AM EDT - 11 months ago

SAB Biotherapeutics Registration statement: Registration Filing

Aug 29, 2025, 8:00 AM EDT - 11 months ago

SAB Biotherapeutics Proxy statement: Proxy Filing

Aug 19, 2025, 8:00 AM EDT - 1 year ago

SAB Biotherapeutics Proxy statement: Proxy Filing

Aug 7, 2025, 7:30 AM EDT - 1 year ago

SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates

Aug 7, 2025, 7:00 AM EDT - 1 year ago

SAB Biotherapeutics Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 1 year ago

SAB Biotherapeutics Quarterly report: Q2 2025

Jul 21, 2025, 7:30 AM EDT - 1 year ago

SAB BIO Announces Oversubscribed $175 Million Private Placement

Jun 2, 2025, 8:00 AM EDT - 1 year ago

SAB Biotherapeutics Proxy statement: Proxy Filing

May 9, 2025, 9:00 AM EDT - 1 year ago

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

May 8, 2025, 6:00 PM EDT - 1 year ago

SAB Biotherapeutics Earnings release: Q1 2025

May 8, 2025, 6:00 PM EDT - 1 year ago

SAB Biotherapeutics Quarterly report: Q1 2025

Mar 31, 2025, 7:32 AM EDT - 1 year ago

SAB BIO Reports Full Year 2024 Operating and Financial Results

Mar 30, 2025, 6:00 PM EDT - 1 year ago

SAB Biotherapeutics Earnings release: Q4 2024

Mar 30, 2025, 6:00 PM EDT - 1 year ago

SAB Biotherapeutics Annual report: Q4 2024

Feb 12, 2025, 10:00 AM EST - 1 year ago

SAB Biotherapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 6, 2025, 2:00 PM EST - 1 year ago

SAB Biotherapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Jan 28, 2025, 7:00 AM EST - 1 year ago

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

Jan 23, 2025, 7:00 AM EST - 1 year ago

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

Nov 19, 2024, 7:00 AM EST - 1 year ago

SAB Biotherapeutics Slides: Corporate Presentation

Nov 6, 2024, 5:05 PM EST - 1 year ago

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

Nov 6, 2024, 7:00 AM EST - 1 year ago

SAB Biotherapeutics Quarterly report: Q3 2024

Nov 6, 2024, 7:00 AM EST - 1 year ago

SAB Biotherapeutics Earnings release: Q3 2024

Sep 13, 2024, 7:00 AM EDT - 2 years ago

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

Sep 9, 2024, 7:00 AM EDT - 2 years ago

SAB Biotherapeutics Press release: Study Update

Sep 9, 2024, 7:00 AM EDT - 2 years ago

SAB Biotherapeutics Slides: Study Update

Sep 4, 2024, 7:05 AM EDT - 2 years ago

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

Aug 8, 2024, 5:51 PM EDT - 2 years ago

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

Aug 8, 2024, 7:00 AM EDT - 2 years ago

SAB Biotherapeutics Earnings release: Q2 2024

Aug 8, 2024, 7:00 AM EDT - 2 years ago

SAB Biotherapeutics Quarterly report: Q2 2024

Aug 5, 2024, 7:30 AM EDT - 2 years ago

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes

Jul 31, 2024, 7:30 AM EDT - 2 years ago

SAB BIO Appoints Lucy To as Chief Financial Officer

Jun 20, 2024, 7:20 AM EDT - 2 years ago

SAb Biotherapeutics Rebrands as SAB BIO

Jun 18, 2024, 1:10 PM EDT - 2 years ago

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

May 30, 2024, 4:45 PM EDT - 2 years ago

SAB Biotherapeutics Announces Departure of Chief Financial Officer

May 30, 2024, 8:00 AM EDT - 2 years ago

SAB Biotherapeutics Proxy statement: Proxy Filing

May 21, 2024, 7:15 AM EDT - 2 years ago

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

May 20, 2024, 5:45 PM EDT - 2 years ago

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates

May 20, 2024, 7:00 AM EDT - 2 years ago

SAB Biotherapeutics Earnings release: Q1 2024

May 20, 2024, 7:00 AM EDT - 2 years ago

SAB Biotherapeutics Quarterly report: Q1 2024

May 6, 2024, 7:15 AM EDT - 2 years ago

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

Apr 16, 2024, 7:15 AM EDT - 2 years ago

SAB Biotherapeutics Provides SAB-142 Trial Update

Apr 8, 2024, 7:15 AM EDT - 2 years ago

SAB Biotherapeutics to Present at INNODIA Annual Meeting

LewisDaKat Jul. 30 at 7:00 PM

0 · Reply

DDiamond_Handz Jul. 30 at 5:41 PM

$SABS 10$ eoy

0 · Reply

JTebow_CWS Jul. 30 at 11:47 AM

$SABS Institutional ownership is up to 90%. Loaded the boat.

0 · Reply

Orlandotrader Jul. 27 at 5:34 PM

$SABS This one is just marking time. Results 2027. No one will commit early in Bio Tech. Patience and load in lower 3$ Range.

0 · Reply

high_tech_texan Jul. 25 at 11:51 AM

2 · Reply

BioRich Jul. 21 at 4:42 PM

0 · Reply

stockboyaisle1 Jul. 21 at 1:24 PM

$SABS This guy does an amazing job of explaining 142: https://x.com/anthonystaj/status/2033274287415517322/video/1?s=46

0 · Reply

gobio Jul. 20 at 3:47 PM

0 · Reply

GlobalMarketBulletin Jul. 18 at 9:06 AM

0 · Reply

GlobalMarketBulletin Jul. 18 at 8:25 AM

2 · Reply

Dubbyy Jul. 17 at 3:39 PM

$SABS good long here

1 · Reply

Nicks_pics Jul. 9 at 3:17 PM

$SABS How is the SABSW volume 222,627 and it’s only moved .0001? There have been no buyers and sellers for those for over a year. 🤷‍♂️

1 · Reply

DDiamond_Handz Jul. 7 at 5:22 PM

$SABS mirroring $SPY agian...

0 · Reply

high_tech_texan Jul. 2 at 1:54 AM

$SABS Several new job openings on their web site.

1 · Reply

BioRich Jul. 1 at 4:40 PM

$CAPR Stocktwits Q2 Quarterly Filing: @BioRich Top 50 portfolio positions: 1) GUTS 2) ABVX 3) IBRX 4) ALT 5) KYTX 6) DAVE 7) CADL 8) MIST 9) UEC 10) OTLK 11) CAPR 12) $TGTX 13) $SABS 14) $NVAX 15) $LEGN 16) VKTX 17) OCUL 18) SOFI 19) BBIO 20) SGP 21) VNDA 22) SHAZ 23) NRXP 24) GPCR 25) EWTX 26) TLSA 27) SKM 28) MLTX 29) SNDX 30) JMIA 31) NKTR 32) VVOS 33) RGNX 35) ARRNF 36) CRMD 37) WVE 38) NUVB 39) SMMT 40) ANNX 41) CGON 42) TEM 43) IVA 44) PSN 45) LGND 46) IMVT 47) MPLT 48)NNE 49) ARDX 50) COGT If I own it, I believe in it. What am I missing? Hold too much? Not enough? Look forward to your feedback! Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

11 · Reply

DDiamond_Handz Jun. 30 at 9:06 PM

$SABS the volume has 10x in recent months and we are still stuck under 4...

0 · Reply

Nicks_pics Jun. 30 at 6:41 PM

$SABS Someone bought 100 warrants today and SABSW is now my best performer. +70.67% 😂🤣 Can’t make this stuff up.

0 · Reply

MUBSN Jun. 29 at 11:30 PM

$SABS I sold here today to increase my position on $CALC . I hope to be back before the rise

0 · Reply

high_tech_texan Jun. 27 at 6:00 PM

$SABS Small sale (988 shares) from Alexandra Kropotova yesterday. It was a "Transaction Code F", which I believe is tax related. https://www.sec.gov/Archives/edgar/data/1825323/000119312526285722/xslF345X06/ownership.xml

0 · Reply

stockboyaisle1 Jun. 27 at 12:09 AM

$SABS Below is SABS volume for today Schwab 5.7 M vs Nasdaq 300 k. Anyone know which is correct or have an explanation to what I’m missing? Thanks

1 · Reply

DDiamond_Handz Jun. 25 at 10:15 PM

$SABS interesting AH here

1 · Reply

MUBSN Jun. 25 at 9:36 AM

$SABS

1 · Reply

Market Cap	263.80M
Revenue (ttm)	0.00
Net Income (ttm)	13.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	208,600
Avg Vol	755,806
Day's Range	N/A - N/A
Shares Out	76.46M
Stochastic %K	31%
Beta	0.52
Analysts	Strong Sell
Price Target	$11.18